Pfizer Inc.'s Premarin for Menopause Linked to Blood Clot Risk

Published: Oct 01, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Pfizer’s Inc. (PFE)’s Premarin for menopause may be tied to a higher risk of blood clots than another common estrogen treatment called estradiol, a study found. Women taking Premarin, also known as conjugated equine estrogens, had double the risk of a blood clot in the veins than women taking estradiol, a synthetic form of estrogen, according to research today in JAMA Internal Medicine. No difference between the treatments was seen in the risk of stroke.

Help employers find you! Check out all the jobs and post your resume.

Back to news